Absorption, distribution, metabolism, and excretion of [ 14 C]BYL719 (alpelisib) in healthy male volunteers

Purpose To determine the pharmacokinetics of the p110α-selective inhibitor alpelisib (BYL719) in humans, to identify metabolites in plasma and excreta, and to characterize pathways of biotransformation.